Regular Meeting of the WMed Institutional Biosafety Committee (IBC)
March 11, 2026
2:00pm - 3:00pm
In person Room 423

Meeting Start Time: The Chair confirmed there was a quorum and the meeting was called to order at 2:04pm.

Number of Regular members on the roster: 10; Number required for quorum: 6

1. Attendance

Voting Members Present	
Status	**Initials**
Chair, Member	NH
Vice Chair, Member	CJ
Member	RV
Member	RP
Member	AC
Member	MC*
IBC Coordinator	CJK

Voting Members Absent	
Status	**Initials**
Community Member	SF
Community Member	RS
Member	JD

Non-Voting Members Present	
Status	**Initials**
SDRC, Ex-officio	CS
RSO, Ex-officio	PJ*

*Attended via Microsoft Teams

2. Welcome and Updates

- NH welcomed members to the meeting.
- CJK now officially a voting member of the IBC.

3. Conflicts of Interest and Confidentiality

The Chair reminded all members present that any member of the IBC may not participate in the review or approval of a project in which he/she has been or expects to be engaged or has a direct financial interest. NH identified conflict of interest for the review of their protocol as well as TR protocol, which they are listed on as personnel. They will recuse themselves during the review of those protocols.

4. Review of Prior Minutes

a. **Approval of 1.27.2026 minutes**

Discussion: No comments.

MOTION: A motion was made by NH and seconded by RP to approve the **1.27.2026** meeting minutes.

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent
6	6	0	0	0	4

RV joined at 2:06pm

5. **Radiation Safety Updates - PJ**
   - **New CT Machine:** The shielding plan submitted to the State of Michigan for installation of the new CT machine has been approved. PJ reported that once the CT machine is installed, radiation leakage measurements will be performed around the room to verify the adequacy of the shielding. The measurement data will then be submitted to the State of Michigan. The radiation registration has already been updated to reflect the new machine.
   - **Lab Closing:** The Vesteron laboratory located at the Innovation Center is closing. The laboratory will require proper decommissioning, and a license amendment will be submitted to the NRC to remove this location from our license.
   - **Radiation Waste:** PJ reported that a significant amount of radioactive waste is currently stored at the Innovation Center. A waste pickup will be scheduled and coordinated with radioactive waste from the Upjohn 5th Floor so that both locations can be serviced at the same time.
   - **Dosimetry Data:** Review of personnel dosimetry data for the previous monitoring period indicated no abnormal or elevated radiation exposures..

PJ left at 2:11pm after Radiation Safety Update
NH recused at 2:13pm, quorum maintained

6. **Protocol Review**
   a. **IBC-2022-025 – NH**

Discussion: The reviewers for this protocol were CJ and RP. CJ provided a brief overview of the proposed project updates. The updates include the addition of new *Streptococcus pneumoniae* serotypes. All strains are clinical isolates and are sensitive to one or more antibiotics. The committee confirmed that the described personal protective equipment (PPE) is adequate to prevent personnel exposure. All work will be conducted at Biosafety Level 2 within either the BSL2 core laboratory or the designated BSL2 space in the Vivarium. Double containment will be utilized during transport of materials between rooms. Minor typographical errors were identified and may be corrected administratively, as they do not affect the scientific content or risk assessment. AC recommended clarifying the face mask requirement by specifying use of a surgical mask.

MOTION: A motion was made by CJ and seconded by RP to approve the protocol.

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent

6	6	0	0	1	3

b. IBC-2022-026 – TR

Discussion: This protocol does not involve activities covered under the NIH Guidelines and does not fall within the expanded scope of the Institutional Biosafety Committee. A full IBC protocol had previously been required due to the lack of an appropriate mechanism to capture this work elsewhere. With the development and implementation of the new IBC registration form, the intent is to transition lower-risk activities to that process rather than requiring a full IBC protocol. The committee will continue to review registration forms at least annually during laboratory inspections, allowing biosafety risks and containment practices to be reviewed and discussed as needed. Based on this discussion, the suggestion is that the protocol be closed and the described work be managed and documented under the IBC registration process going forward.

NH rejoined at 2:24pm

c. IBC-2023-002 – AA

Discussion: The reviewers for this protocol were NH and CJK. Proposed changes include updates to study personnel and modifications to the bacterial strains. The project involves testing the antimicrobial properties of nanoparticles against *Staphylococcus aureus, Staphylococcus epidermidis,* and *Escherichia coli*. Nanoparticles, nanoparticle-constructed mesh materials, or mesh coated with nanoparticles will be placed on inoculated agar plates to evaluate bacterial inhibition using Zone of Inhibition (ZOI) testing. Bacterial strains designated as Biosafety Level 2 will be handled exclusively within the BSL2 core laboratory. The risk of infection is low and that the described disinfection procedures are appropriate. Recommended clarifying the type of surgical mask to be used in the PPE description. Additionally, all personnel listed on the protocol must complete required CITI training prior to protocol approval.

MOTION: A motion was made by NH and seconded by RV to approve.

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent
7	7	0	0	0	3

d. IBC-2023-001 – TR

Discussion: The reviewers for this protocol were RP and RV. Proposed changes include updates to study personnel and the inclusion of the same work and assays to be conducted using extracellular vesicles (EVs). All personnel listed on the protocol must complete required CITI training prior to protocol approval. Reviewers also recommended clarifying the specific type of surgical mask to be used in the PPE description. Minor typographical errors were identified throughout the protocol and may be corrected administratively, as they do not impact the study design or biosafety risk assessment.

MOTION: A motion was made by RP and seconded by RV to approve.

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent

7	7	0	0	0	3

e. IBC-2026-001 – EL

Discussion: The reviewers for this new protocol submission were MC and NH. The proposed study aims to investigate autosomal dominant polycystic kidney disease (ADPKD) through development of in vitro model systems. The protocol involves the use of multiple human and mouse cell lines and various approaches to gene modification, including CRISPR-mediated gene knock-in and knock-out of genes believed to be involved in ADPKD pathogenesis. Risks of the approach are minimized by not using a lentiviral vector system. Instead, gene delivery will be performed using electroporation and chemical lipofectamine based transfection methods. Some of the cell lines utilized have been immortalized using the SV40 T-antigen method. Reviewers noted that additional detail is needed regarding the specific genetic targets and modifications planned for the CRISPR knock-in experiments.

Medification required:

- Secondary containment procedures and designated transport routes between floors must be clearly specified to ensure safe movement of materials.
- Protocol language should be simplified where possible to ensure the study design, methods, and risks are understandable to all reviewers, including community and non-scientist members.
- Additional detail must be provided regarding the specific genomic targets and modifications proposed, including the genes being targeted and the methods to be used.
    - Detailed targeting information is essential for risk assessment and management
- CITI training must be completed by all members listed on the protocol
    - Gregory Van Den Huevel – Biomedical Sciences RCR
    - Jerry Bouma – Biomedical Sciences RCR

MOTION: A motion was made by RP and seconded by NH to require modifications to the protocol.

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent
7	7	0	0	0	3

7. Occupation Health Updates - JD

- OSHA inspection updates were provided to the committee via email by JD. A brief overview of the inspection by AC, who was present on site during the OSHA visit. The OSHA inspector requested documentation related to formalin handling procedures, exposure monitoring, and training records. Exposure monitoring was also conducted during the inspection. Exposure monitoring results have not yet been received, and the final report is not expected until May. The committee will be updated as additional information becomes available.

8. Biosafety Updates - AC

- **Annual Laboratory Inspections:** AC reported that annual laboratory inspections have been completed for 4th and 5th floor. Follow-up is ongoing to address minor corrective actions identified during inspections for individual laboratories.

9. IBC General Updates:

- **Scheduling Meeting for April:** CJK taking suggestions for dates/times for scheduling a meeting in April. A meeting is required to review EL's second protocol submission
- **Triennial for 2026:** CJK reviewed the remaining triennial protocol renewals scheduled for 2026. This includes two protocols for NH, one of which will transition to the IBC laboratory registration process, and four protocols for MY. Three of MY's protocols are planned to be consolidated into a single protocol at the time of renewal.

10. Adjournment:

Meeting ended at 3:10pm.